Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for XORTX Therapeutics Inc. (XRTX : NSDQ)

• Company Description    XORTX Therapeutics Inc. is a pharmaceutical therapeutics company. It focused on developing therapies to treat progressive kidney disease. XORTX Therapeutics Inc. is based in CALGARY, Alberta. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $2.18 Daily Weekly Monthly 20 Day Moving Average: 61,491 shares Shares Outstanding: 1.55 (millions) Market Capitalization: $3.37 (millions) Beta: 0.80 52 Week High: $7.05 52 Week Low: $1.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.30% -25.14% 12 Week 7.92% -0.23% Year To Date -22.42% -24.42%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3710 - 33RD STREET NW - ALBERTA,A1 T2L 2M1 CAN ph: 403-455-7727 fax: - adavidoff@xortx.com http://www.xortx.com

• General Corporate Information    Officers Allen Davidoff - Chief Executive Officer and President Anthony J. Giovinazzo - Non-Executive Chair Michael Bumby - Chief Financial Officer William Farley - Director Abigail Jenkins - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98420Q405 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 1.55 Most Recent Split Date: 4.00 (0.20:1) Beta: 0.80 Market Capitalization: $3.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.63 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 38.95% vs. Previous Quarter: -28.89% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -150.01 12/31/25 - -120.32 09/30/25 - -77.08 ROA 03/31/26 - -106.53 12/31/25 - -90.53 09/30/25 - -59.12 Current Ratio 03/31/26 - 0.86 12/31/25 - 2.11 09/30/25 - 1.62 Quick Ratio 03/31/26 - - 12/31/25 - 2.11 09/30/25 - 1.62 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.83 12/31/25 - 1.50 09/30/25 - 1.89 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©